Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales in the antibody-related business increased due to the continued adoption of ELISA kits for clinical trials conducted by overseas CRO companies, the weaker yen, sizeable antibody sales to major diagnostic reagent manufacturers, and higher sales from contract services and the company's own in vitro diagnostic product-related business. Profitability improved along with the increase in net sales. Meanwhile, sales of testing services, TG silkworm services, and the cosmetics-related business decreased.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥563 million (YoY +16.0%) |
| Operating profit | ¥197 million (YoY +38.9%) |
| Ordinary income | ¥206 million (YoY +38.1%) |
| Profit attributable to owners of the parent | ¥186 million (YoY +31.7%) |
| Net income per share | ¥20.03 |
| Equity ratio | End of the current fiscal period 86.4 / End of previous period 85.5 |
| Total assets | ¥2,285 million |
| Net assets | ¥1,974 million |
| Cash flows from operating activities | ¥173,572 thousand |
| Cash flows from investing activities | ¥-216,700 thousand |
| Cash flows from financing activities | ¥-63,215 thousand |
| Cash and cash equivalents at end of period | ¥822,660 thousand |
| Full-year earnings forecast | Net Sales ¥1,087 million (YoY +8.2%) / Operating profit ¥322 million (YoY +14.5%) / Ordinary income ¥322 million (YoY +7.1%) / Profit attributable to owners of the parent ¥347 million (YoY +5.5%) |
| Annual Dividend Forecast | ¥6 → ¥7.5（+25.0%） |
| Segment revenue | Antibody-related business ¥562,137 thousand (YoY +16.1%), Cosmetics-related business ¥1,031 thousand (YoY -25.5%) |
| Segment profit | Antibody-related business ¥198,549 thousand (YoY +39.4%), Cosmetics-related business ¥-1,071 thousand |
| Depreciation and amortization | ¥9,184 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses on Investment Securities ¥11,847 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New — companies / Excluded — companies / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者: none) |
| Issued Shares at Period-End | 9,314,590 Shares |
| Treasury Shares at Period-End | 1,132 Shares |
| Factors Behind Changes in Business Performance | Sales in the antibody-related business increased due to the continued adoption of ELISA kits for clinical trials conducted by overseas CRO companies, the weaker yen, sizeable antibody sales to major diagnostic reagent manufacturers, and higher sales from contract services and the company's own in vitro diagnostic product-related business. Profitability improved along with the increase in net sales. Meanwhile, sales of testing services, TG silkworm services, and the cosmetics-related business decreased. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Overseas sales increased as ELISA kits continued to be adopted for clinical trials conducted by overseas CRO companies, supported by the weaker yen. Sales of antibodies in sizeable lots to major diagnostic reagent manufacturers, contract services, and the company's own in vitro diagnostic product-related business also increased. Gross profit increased along with net sales, improving profitability. Ordinary profit included a foreign exchange loss, while insurance surrender value refunds and income from subsidies and other sources were recorded.